De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study.
暂无分享，去创建一个
N. Harbeck | O. Gluz | S. Kuemmel | H. Kreipe | A. Hartkopf | R. Kates | U. Nitz | R. Wuerstlein | M. Christgen | J. Potenberg | M. Graeser | P. Wuelfing | J. Holtschmidt | M. Just | K. Luedtke-heckenkamp | Jan Priel | R. Schumann